Top

Published in:

01-10-2021 | Systemic Lupus Erythematosus | Original Research

A Retrospective Analysis of Longitudinal Changes in Bone Mineral Density in Women with Systemic Lupus Erythematosus

Authors: Claudia Mendoza-Pinto, Mario García-Carrasco, Daniela Juárez-Melchor, Pamela Munguía-Realpozo, Ivet Etchegaray-Morales, Nicolás Santiago-Martín, Jorge Ayón-Aguilar, Socorro Méndez-Martínez

Published in: Calcified Tissue International | Issue 4/2021

Abstract

Most prospective studies of bone mineral density (BMD) in systemic lupus erythematosus (SLE) patients have been of relatively short duration, with a maximum of 6 years. To describe long-term changes in BMD in women with SLE and identify risk factors associated with BMD loss. We retrospectively evaluated 132 adult Mexican-Mestizo women with SLE who underwent dual X-ray absorptiometry (DXA). Demographic and clinical data were collected and BMD at the lumbar spine (L1–L4) and total hip were collected at baseline and during the follow up. At baseline, the mean age of participants was 43.4 ± 12.5 years, 50.8% had osteopenia and 11% osteoporosis. The median follow-up was 13 (IQR 10.2–14.0) years. During follow up, 79% of patients used glucocorticoid (GCT). The mean percentage of changes in BMD during follow up were: − 14.03 ± 11.25% (− 1.49%/year) at the lumbar spine, and − 15.77 ± 11.57% (− 1.78%/year) at the total hip, with significant changes (p < 0.001 for both comparisons). Multivariate analysis showed older age, GCT use at baseline, and transition to the menopause during the follow-up were significantly associated with greater reductions in BMD. This retrospective longitudinal study found significant BMD loss at the lumbar spine and hip. Older age, menopausal transition and GCT use were independently associated with BMD decline in women with SLE.

Available only for authorised users

Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R et al (2010) European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 69:1269–1274. https://doi.org/10.1136/ard.2009.117200CrossRefPubMed

Keeling SO, Alabdurubalnabi Z, Avina-Zubieta A, Barr S, Bergeron L, Bernatsky S et al (2018) Canadian Rheumatology Association recommendations for the assessment and monitoring of systemic lupus erythematosus. J Rheumatol 45:1426–1439. https://doi.org/10.3899/jrheum.171459CrossRefPubMed

Kalla AA, Fataar AB, Jessop SJ, Bewerunge L (1993) Loss of trabecular bone mineral density in systemic lupus erythematosus. Arthritis Rheum 36:1726–1734CrossRefPubMed

Pineau CA, Urowitz MB, Fortin PJ et al (2004) Osteoporosis in systemic lupus erythematosus: factors associated with referral for bone mineral density studies, prevalence of osteoporosis and factors associated with reduced bone density. Lupus 13:436–441. https://doi.org/10.1191/0961203303lu1036oaCrossRefPubMed

Almehed K, Forsblad d’Elia H, Kvist G, Ohlsson C, Carlsten H (2007) Prevalence and risk factors of osteoporosis in female SLE patients—extended report. Rheumatology 46:1185–1190. https://doi.org/10.1093/rheumatology/kem105CrossRefPubMed

Bultink IEM, Lems WF, Kostense PJ, Dijkmans B, Voskuyl AE (2005) Prevalence of and risk factors for low bone mineral density and vertebral fractures in patients with systemic lupus erythematosus. Arthritis Rheum 52:2044–2050. https://doi.org/10.1002/art.21110CrossRefPubMed

Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Escárcega RO, Jiménez-Hernández M, Etchegaray-Morales I et al (2009) Risks factors for low bone mineral density in pre-menopausal Mexican women with systemic lupus erythematosus. Clin Rheumatol. https://doi.org/10.1007/s10067-008-0984-zCrossRefPubMed

Jardinet D, Lefebvre C, Depresseux G et al (2000) Longitudinal analysis of bone mineral density in pre-menopausal female systemic lupus erythematosus patients: deleterious role of glucocorticoid therapy at the lumbar spine. Rheumatology (Oxford, England) 39:389–392CrossRef

Boyanov M, Robeva R, Popivanov P (2003) Bone mineral density changes in women with systemic lupus erythematosus. Clin Rheumatol 22:318–323. https://doi.org/10.1007/s10067-003-0743-0CrossRefPubMed

10.

Jacobs J, Korswagen LA, Schilder AM, Van Tuyl LH, Dijkmans BAC, Lems WF et al (2013) Six-year follow-up study of bone mineral density in patients with systemic lupus erythematosus. Osteoporos Int 24:1827–1833. https://doi.org/10.1007/s00198-012-2157-9CrossRefPubMed

11.

Zhu TY, Griffith JF, Au S-K, Tang X-L, Kwok AW, Leung P-C et al (2014) Bone mineral density change in systemic lupus erythematosus: a 5-year followup study. J Rheumatol 41:1990–1997. https://doi.org/10.3899/jrheum.131190CrossRefPubMed

12.

Bultink IEM, Lems WF (2015) Systemic lupus erythematosus and fractures. RMD Open 1:e000069. https://doi.org/10.1136/rmdopen-2015-000069CrossRefPubMedPubMedCentral

13.

Mendoza-Pinto C, García-Carrasco M, Sandoval-Cruz H, Muñoz-Guarneros M, Escárcega RO, Jiménez-Hernández M et al (2009) Risk factors of vertebral fractures in women with systemic lupus erythematosus. Clin Rheumatol 28:579–585. https://doi.org/10.1007/s10067-009-1105-3CrossRefPubMed

14.

García-Carrasco M, Mendoza-Pinto C, León-Vázquez ML, Méndez-Martínez S, Etchegaray-Morales I, Montiel-Jarquín Á et al (2017) Incidence of vertebral fractures in women with systemic lupus erythematosus after 8 years of follow-up. Calcif Tissue Int. https://doi.org/10.1007/s00223-017-0286-zCrossRefPubMed

15.

Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40:1725. https://doi.org/10.1002/art.1780400928CrossRefPubMed

16.

Petri M, Orbai A-M, Alarcón GS et al (2012) Derivation and validation of the systemic lupus international collaborating clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 64:2677–2686. https://doi.org/10.1002/art.34473.DerivationCrossRefPubMedPubMedCentral

17.

Ceccarelli F, Orefice V, Perrone G, Pirone C, Perricone C, Truglia S et al (2020) Premature ovarian failure in patients affected by systemic lupus erythematosus: a cross-sectional study. Clin Exp Rheumatol 38:450–454PubMed

18.

Guzman J, Cardiel MH, Arce-Salinas A, Sanchez-Guerrero J, Alarcon-Segovia D (1992) Measurement of disease activity in systemic lupus erythematosus. Prospective validation of 3 clinical indices. J Rheumatol 19:1551–1558PubMed

19.

Gladman DD, Goldsmith CH, Urowitz MB, Bacon P, Fortin P, Ginzler E et al (2000) The systemic lupus International Collaborating Clinics/American College of Rheumatology (SLICC/ACR) Damage Index for Systemic Lupus Erythematosus International Comparison. J Rheumatol 27:373–376PubMed

20.

Holick MF (2007) Vitamin D deficiency. N Engl J Med 357:266–281. https://doi.org/10.1136/bmj.318.7193.1284aCrossRefPubMed

21.

Shuhart CR, Yeap SS, Anderson PA, Jankowski LG, Lewiecki EM, Morse LR et al (2019) Executive summary of the 2019 ISCD position development conference on monitoring treatment, DXA cross-calibration and least significant change, spinal cord injury, peri-prosthetic and orthopedic bone health, transgender medicine, and pediatrics. J Clin Densitom Off J Int Soc Clin Densitom 22:453–471. https://doi.org/10.1016/j.jocd.2019.07.001CrossRef

22.

Pons F, Peris P, Guañabens N, Font J, Huguet M, Espinosa G et al (1995) The effect of systemic lupus erythematosus and long-term steroid therapy on bone mass in pre-menopausal women. Br J Rheumatol 34:742–746. https://doi.org/10.1093/rheumatology/34.8.742CrossRefPubMed

23.

Hansen M, Halberg P, Kollerup G, Pedersen-Zbinden B, Hørslev-Petersen K, Hyldstrup L et al (1998) Bone metabolism in patients with systemic lupus erythematosus. Effect of disease activity and glucocorticoid treatment. Scand J Rheumatol 27:197–206. https://doi.org/10.1080/030097498440813CrossRefPubMed

24.

Kipen Y, Briganti EM, Strauss BJ, Littlejohn GO, Morand EF (1999) Three year follow-up of body composition changes in pre-menopausal women with systemic lupus erythematosus. Rheumatology (Oxford) 38:59–65. https://doi.org/10.1093/rheumatology/38.1.59CrossRef

25.

Ho SC, Chan SG, Yip YB, Chan CSY, Woo JLF, Sham A (2008) Change in bone mineral density and its determinants in pre- and perimenopausal Chinese women: the Hong Kong Perimenopausal Women Osteoporosis Study. Osteoporos Int J Establ Result Coop Between Eur Found Osteoporos Natl Osteoporos Found USA 19:1785–1796. https://doi.org/10.1007/s00198-008-0614-2CrossRef

26.

Johansson H, Clark P, Carlos F, Oden A, McCloskey EV, Kanis JA (2011) Increasing age- and sex-specific rates of hip fracture in Mexico: a survey of the Mexican institute of social security. Osteoporos Int 22:2359–2364. https://doi.org/10.1007/s00198-010-1475-zCrossRefPubMed

27.

Karlamangla AS, Burnett-Bowie S-AM, Crandall CJ (2018) Bone health during the menopause transition and beyond. Obstet Gynecol Clin N Am 45:695–708. https://doi.org/10.1016/j.ogc.2018.07.012CrossRef

28.

Camacho PM, Petak SM, Binkley N, Clarke BL, Harris ST, Hurley DL et al (2016) American Association of Clinical Endocrinologists and American College of Endocrinology Clinical Practice Guidelines for the diagnosis and treatment of postmenopausal osteoporosis—2016. Endocr Pract Off J Am Coll Endocrinol Am Assoc Clin Endocrinol 22:1–42. https://doi.org/10.4158/EP161435.GLCrossRef

29.

Mak A, Lim JQ, Liu Y, Cheak AA, Ho RC (2013) Significantly higher estimated 10-year probability of fracture in lupus patients with bone mineral density comparable to that of healthy individuals. Rheumatol Int 33:299–307. https://doi.org/10.1007/s00296-012-2389-1CrossRefPubMed

30.

Lee C, Almagor O, Dunlop DD, Manzi S, Spies S, Chadha AB et al (2006) Disease damage and low bone mineral density: an analysis of women with systemic lupus erythematosus ever and never receiving corticosteroids. Rheumatology (Oxford) 45:53–60. https://doi.org/10.1093/rheumatology/kei079CrossRef

31.

Bultink IEM (2018) Bone disease in connective tissue disease/systemic lupus erythematosus. Calcif Tissue Int 102:575–591. https://doi.org/10.1007/s00223-017-0322-zCrossRefPubMed

32.

Mendoza-Pinto C, Rojas-Villarraga A, Molano-González N, Jiménez-Herrera EA, León-Vázquez ML, Montiel-Jarquín Á et al (2018) Bone mineral density and vertebral fractures in patients with systemic lupus erythematosus: a systematic review and meta-regression. PloS One 13:e0196113. https://doi.org/10.1371/journal.pone.0196113CrossRefPubMedPubMedCentral

33.

McCloskey EV, Odén A, Harvey NC, Leslie WD, Hans D, Johansson H et al (2016) A meta-analysis of trabecular bone score in fracture risk prediction and its relationship to FRAX. J Bone Miner Res Off J Am Soc Bone Miner Res 31:940–948. https://doi.org/10.1002/jbmr.2734CrossRef

34.

Buckley L, Guyatt G, Fink HA, Cannon M, Grossman J, Hansen KE et al (2017) 2017 American College of Rheumatology Guideline for the prevention and treatment of glucocorticoid-induced osteoporosis. Arthritis Care Res 69:1095–1110. https://doi.org/10.1002/acr.23279CrossRef

35.

Compston J, Cooper A, Cooper C, Gittoes N, Gregson C, Harvey N et al (2017) UK clinical guideline for the prevention and treatment of osteoporosis. Arch Osteoporos 12:43. https://doi.org/10.1007/s11657-017-0324-5CrossRefPubMedPubMedCentral

36.

Demas KL, Keenan BT, Solomon DH, Yazdany J, Costenbader KH (2010) Osteoporosis and cardiovascular disease care in systemic lupus erythematosus according to new quality indicators. Semin Arthritis Rheum 40:193–200. https://doi.org/10.1016/j.semarthrit.2010.01.001CrossRefPubMedPubMedCentral

37.

Schmajuk G, Yelin E, Chakravarty E, Nelson LM, Panopolis P, Yazdany J (2010) Osteoporosis screening, prevention, and treatment in systemic lupus erythematosus: application of the systemic lupus erythematosus quality indicators. Arthritis Care Res 62:993–1001. https://doi.org/10.1002/acr.20150CrossRef

38.

Casey C, Chung CP, Crofford LJ, Barnado A (2017) Rheumatologists’ perception of systemic lupus erythematosus quality indicators: significant interest and perceived barriers. Clin Rheumatol 36:97–102. https://doi.org/10.1007/s10067-016-3487-3CrossRefPubMed

39.

Lakshminarayanan S, Walsh S, Mohanraj M, Rothfield N (2001) Factors associated with low bone mineral density in female patients with systemic lupus erythematosus. J Rheumatol 28:102–108PubMed

40.

Mok CC, Mak A, Ma KM (2005) Bone mineral density in postmenopausal Chinese patients with systemic lupus erythematosus. Lupus 14:106–112. https://doi.org/10.1191/0961203305lu2039oaCrossRefPubMed

41.

Mok CC, Ying SKY, To CH, Ma KM (2008) Bone mineral density and body composition in men with systemic lupus erythematosus: a case control study. Bone 43:327–331. https://doi.org/10.1016/j.bone.2008.04.003CrossRefPubMed

42.

Huisman AM, White KP, Algra A, Harth M, Vieth R, Jacobs JW et al (2001) Vitamin D levels in women with systemic lupus erythematosus and fibromyalgia. J Rheumatol 28:2535–2539PubMed

43.

Xiu Y, Xu H, Zhao C, Li J, Morita Y, Yao Z et al (2014) Chloroquine reduces osteoclastogenesis in murine osteoporosis by preventing TRAF3 degradation. J Clin Investig 124:297–310. https://doi.org/10.1172/JCI66947CrossRefPubMed

44.

Both T, Zillikens MC, Schreuders-Koedam M, Vis M, Lam W-K, Weel AEAM et al (2018) Hydroxychloroquine affects bone resorption both in vitro and in vivo. J Cell Physiol 233:1424–1433. https://doi.org/10.1002/jcp.26028CrossRefPubMed

Title: A Retrospective Analysis of Longitudinal Changes in Bone Mineral Density in Women with Systemic Lupus Erythematosus
Authors: Claudia Mendoza-Pinto
Mario García-Carrasco
Daniela Juárez-Melchor
Pamela Munguía-Realpozo
Ivet Etchegaray-Morales
Nicolás Santiago-Martín
Jorge Ayón-Aguilar
Socorro Méndez-Martínez
Publication date: 01-10-2021
Publisher: Springer US
Keywords: Systemic Lupus Erythematosus
Glucocorticoid
Osteoporosis
Osteoporosis
Published in: Calcified Tissue International / Issue 4/2021
Print ISSN: 0171-967X
Electronic ISSN: 1432-0827
DOI: https://doi.org/10.1007/s00223-021-00845-0

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 4/2021

Diagnosis and Management of Osteoporosis During COVID-19: Systematic Review and Practical Guidance

Musculoskeletal Benefits from a Physical Activity Program in Primary School are Retained 4 Years after the Program is Terminated

Maintained Bone Density in Young Hypoestrogenized Women with a High BMI: Case Series

Psychometric Properties of the Chinese Version of the Sarcopenia and Quality of Life, a Quality of Life Questionnaire Specific for Sarcopenia

Quantitative Evaluation of Osteocyte Morphology and Bone Anisotropic Extracellular Matrix in Rat Femur

Specific MicroRNAs Found in Extracellular Matrix Vesicles Regulate Proliferation and Differentiation in Growth Plate Chondrocytes

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials